Pediatric Solid Tumor Clinical Trial
Official title:
A Prediction Model of Hematological Recovery After High-dose Chemotherapy in Pediatric Solid Tumor : Data Collection and Model Validation
NCT number | NCT05024331 |
Other study ID # | 2021-02-059 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | July 30, 2021 |
Est. completion date | August 12, 2021 |
Verified date | July 2021 |
Source | Samsung Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This study aims to compare and evaluate the predicted values of the participants, and the algorithm predicted values of ANC level reduction periods after high-capacity chemotherapy in pediatric solid tumor patients. The participants are pediatricians who voluntarily participate in this study and consent to this study.
Status | Completed |
Enrollment | 10 |
Est. completion date | August 12, 2021 |
Est. primary completion date | July 30, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: - physician who is working at Samsung Medical Center as a pediatric doctor - A person who voluntarily agrees to participate in the study Exclusion Criteria: - Those who disagree with the study |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Samsung Medical Centre | Seoul |
Lead Sponsor | Collaborator |
---|---|
Samsung Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | accuracy of algorithm | primary outcome is the difference between result of algorithm and prediction values of doctors.
total number of pediatric patients who performed chemotherapy and high-capacity chemotherapy at Samsung Medical Center in 2019-2020 - (Exclusion such as insufficient data or death) +10 reliability check questions expected to be approximately 100 questions The test based on data consisting of blood test results from approximately 100 patients, is recorded in anticipation of the first date (recovery date) of a day when ANC levels over 500 last more than 3 days. |
This clinical trial is conducted in one day, and the Survey is conducted after completing the test using data from 99 pediatric patients. | |
Primary | A quantitative study on usability | We would like to ask 17 questions to identify the user's thoughts on AI and how they affect change of opinion. The following are examples are as follows:
Do you think you can easily adapt to new technologies or programs? Do you value subjective thoughts and experiences over other people's opinions in your work? Do you tend to browse information online when making decisions during work? Apart from this study, are you positive about the use of predictive models in clinical trials? Do you think the items and information in the given data are sufficient to predict the values you want to predict? |
This clinical trial is conducted in one day, and the Survey is conducted after completing the test using data from 99 pediatric patients. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05151718 -
Multiomic Approach to Radioresistance of Ependymomas in Children and Adolescents
|
||
Recruiting |
NCT02787876 -
Pegteograstim in Children With Solid Tumors
|
Phase 2 | |
Recruiting |
NCT04222413 -
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05620862 -
Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02520713 -
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
|
||
Recruiting |
NCT05468359 -
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
|
Phase 1/Phase 2 | |
Completed |
NCT04944875 -
Effects of Music and Maternal Voice on Sedation Depth and Sedative Use During Pediatric Magnetic Resonance Imaging.
|
N/A | |
Recruiting |
NCT03618381 -
EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
|
Phase 1 | |
Recruiting |
NCT04897321 -
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
|
Phase 1 | |
Active, not recruiting |
NCT04483778 -
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
|
Phase 1 | |
Active, not recruiting |
NCT04239040 -
GVAX Plus Checkpoint Blockade in Neuroblastoma
|
Phase 1 | |
Recruiting |
NCT03739827 -
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
|
||
Recruiting |
NCT02339753 -
Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT03222258 -
Prospective Cohort Study Depending on the Use of Palliative Care for Advanced Stage of Cancer Patients
|
||
Completed |
NCT02564198 -
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03273829 -
Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed or Refractory Solid Tumors and Leukemias
|
Phase 1 | |
Completed |
NCT03455140 -
A Study Evaluating the Safety and Activity of Pegylated Recombinant Human Arginase (BCT-100)
|
Phase 1/Phase 2 | |
Completed |
NCT01853345 -
iCAT for Recurrent/Refractory/HR Solid Tumors
|
N/A | |
Active, not recruiting |
NCT03478462 -
Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma
|
Phase 1 | |
Not yet recruiting |
NCT05322187 -
Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
|
Phase 2/Phase 3 |